NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL, SLL

The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL), for treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The AJMC asked Precision’s Erin Lopata to weigh in on how to respond when a drug is added to NCCN guidelines before the FDA approves the indication.

Read the full article here!